Tilray, a global leader in medical cannabis research and production, today announced that initial shipments of the company’s medical cannabis products have arrived in Chile, where they are now available for authorized patients to access. The products are initially available at select pharmacies in Santiago. This marks the first time a North American cannabis producer has successfully distributed full-spectrum cannabis-based medicines to patients through pharmacies in the Americas.
Tilray has partnered with Alef Biotechnology SpA to import and distribute medical cannabis products in Chile, where law permits patients to access medical cannabis under the supervision of a recommending physician. Tilray products in Chile will be distributed only to patients with prescriptions under a series of safeguards to promote safe and responsible use. Alef is licensed by the Chilean government to commercially produce medical cannabis. Tilray announced its partnership with Alef in February 2017.
“Alef Biotechnology is committed to improving the quality of life of patients in need,” said Roberto Roizman, President of the Alef Biotechnology Board. “By importing Tilray’s medical cannabis products to Chile we intend to ease the suffering of those in need by offering pure, precise and predictable medical cannabis products.”
Tilray currently supplies pharmaceutical-grade medical cannabis products – including whole flower, oils and capsules – to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world for commercial, compassionate access and research purposes. In 2017, the company is focused on expanding global distribution of its products to additional countries in Europe and Latin America.
Tilray is a global leader in medical cannabis research and production dedicated to advancing the science, safety, and efficacy of medical cannabis. The company operates one of the largest and most sophisticated federally licensed medical cannabis cultivation facilities in the world, offering a range of products to patients, physicians, pharmacies, governments, hospitals and researchers in Australia, Canada, the European Union and Latin America.
About Alef Biotechnology
Alef Biotechnology is licensed by the Chilean government to commercially produce and distribute medical cannabis. The company is focused on medical cannabis research and development for the treatment of various medical condition. Its purpose is to increase the quality of life of those in pain, bringing dignity by developing innovative drugs and novel drug delivery systems to the market.
Source: 420Intel – Medical Cannabis